Detection of antibodies against benzo[a]pyrene in blood sera of lung cancer patients by ELISA using human recombinant idiotypic and anti-idiotypic antibodies

Authors

  • A.E. Studennikov ederal State Scientific Institute, Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences, Institute of Human Ecology
  • A.N. Glushkov ederal State Scientific Institute, Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences, Institute of Human Ecology
  • V.A. Ustinov Federal State Scientific Institute, Federal Research Centre of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences, Institute of Human Ecology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17126

Keywords:

anti-idiotypic antibodies, ELISA, idiotypic antibodies, IgG, lung cancer, polycyclic aromatic hydrocarbons

Abstract

Summary. Aim of this study was to develop and apply an ELISA method for assessment of the levels of endogenous antibodies against benzo[a]pyrene (Bp) in blood sera of lung cancer (LC) patients. Materials and Methods: ELISA was developed and applied for the detection of endogenous idiotypic and anti-idiotypic antibodies against Bp in human blood sera using recombinant human idiotypic and anti-idiotypic antibodies against Bp. Results: Serum samples of LC patients (n = 22) and healthy donors (n = 24) were analyzed by the new method. Statistical analysis showed that in sera of LC patients the levels of endogenous idiotypic and anti-idiotypic antibodies against Bp were significantly higher than in healthy donors. A logistic regression model for the LC detection utilizing such predictors as the serum levels of idiotypic and anti-idiotypic antibodies against Bp, smoking status, and age, identified LC patients with 83% specificity and 82% sensitivity. Conclusion: The proposed method could be further developed as additional lung cancer screening tool.

References

Tiwari M, Sahu SK, Pandit GG. Distribution of PAHs in different compartment of creek ecosystem: Ecotoxicological concern and human health risk. Environ Toxicol Pharmacol 2017; 50: 58–66. https://doi.org/10.1016/j.etap.2017.01.008

Kim KH, Jahan SA, Kabir E, et al. A review of airborne polycyclic aromatic hydrocarbons (PAHs) and their human health effects. Environ Int 2013; 60: 71–80. https://doi.org/10.1016/j.envint.2013.07.019

Du J, Jing C. Anthropogenic PAHs in lake sediments: a literature review (2002–2018). Environ Sci Process Impacts 2018; 20: 1649–66. https://doi.org/10.1039/c8em00195b

Carter-Harris L, Brandzel S, Wernli KJ, et al. A qualitative study exploring why individuals opt out of lung cancer screening. Fam Pract 2017; 34: 239–44. https://doi.org/10.1093/fampra/cmw146

Quaife SL, Vrinten C, Ruparel M, et al. Smokers’ interest in a lung cancer screening programme: a national survey in England. BMC Cancer 2018; 18: 497. https://doi.org/10.1186/s12885-018-4430-6

Gibbs GW, Labrèche F, Busque MA, et al. Mortality and cancer incidence in aluminum smelter workers: a 5-year update. J Occup Environ Med 2014; 56: 739–64. https://doi.org/10.1097/jom.0000000000000175

Zhang S, Zhang W, Wang K, et al. Concentration, distribution and source apportionment of atmospheric polycyclic aromatic hydrocarbons in the southeast suburb of Beijing, China. Environ Monit Assess 2009; 151: 197–207. https://doi.org/10.1007/s10661-008-0261-2

Campo L, Vimercati L, Carrus A, et al. Fustinoni Environmental and biological monitoring of PAHs exposure in coke-oven workers at the Taranto plant compared to two groups from the general population of Apulia, Italy. Med Lav 2012; 103: 347–60.

Maitre A, Petit P, Marques M, et al. Exporisq-HAP database: 20 years of monitoring French occupational exposure to polycyclic aromatic hydrocarbon mixtures and identification of exposure determinants. Int J Hyg Environ Health 2018; 221: 334–46. https://doi.org/10.1016/j.ijheh.2017.12.008

Mizwar A, Trihadiningrum Y. PAH contamination in soils adjacent to a coal-transporting facility in Tapin district, south Kalimantan, Indonesia. Arch Environ Contam Toxicol 2015; 69: 62–8. https://doi.org/10.1007/s00244-015-0141-z

Schellenberger MT, Grova N, Willième S, et al. Modulation of benzo[a]pyrene induced immunotoxicity in mice actively immunized with a B[a]P-diphtheria toxoid conjugate. Toxicol Appl Pharmacol 2009; 240: 37–45. https://doi.org/10.1016/j.taap.2009.06.019

De Buck SS, Bouche FB, Brandenburger A, et al. Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis. Carcinogenesis 2005; 26: 835–44. https://doi.org/10.1093/carcin/bgi010

Glushkov AN. Immunological disbalance in carcinogenesis. Med Hypotheses 2014; 83: 166–71. https://doi.org/10.1016/j.mehy.2014.05.003

Glushkov AN, Polenok EG, Ustinov VA. Immunomodulation of human carcinogenesis by the blood serum antibodies against benzo[a]pyrene, estradiol and progesterone. Open Journal of Immunology 2016; 6: 67–72. https://doi.org/10.4236/oji.2016.63007

Ustinov VA, Matveeva VA, Kostyanko MA, et al. Antibodies against benzo[a]pyrene in immunized mouse and in lung cancer patients. Exp Oncol 2013; 35: 207–10.

Grebenshchikov IS, Studennikov AE, Ivanov VI, et al. Idiotypic and anti-idiotypic antibodies against polycyclic aromatic hydrocarbon in human blood serum are new biomarkers of lung cancer. Oncotarget 2019; 10: 5070–81. doi: org/10.18632/oncotarget.27126

Kostyanko MV, Glushkov AN. Synthesis of hapten-protein conjugate. Patent RF 1998; 2141114.

Ustinov VA, Averjanov AV, Glushkov AN. Purification and characterization of mouse single-chain antibody against polycyclic aromatic hydrocarbons. J Immunoassay Immunochem 2014; 35: 428–41. https://doi.org/10.1080/15321819.2014.885449

Ustinov VA, Studennikov AE, Vavilov VA, et al. Generation and characterization of human single-chain antibodies against polycyclic aromatic hydrocarbons. Immunological Investigations 2015; 44: 536–52. https://doi.org/10.3109/08820139.2015.1043669

Studennikov AE, Ustinov VA, Morozova VV, et al. New human single chain anti-idiotypic antibody against bezo[a]pyrene. Cent Europ J Immunol 2017; 42: 123–30. https://doi.org/10.5114/ceji.2017.69353

Laemmly UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5. https://doi.org/10.1038/227680a0

Glushkov AN, Kostyanko MV, Cherno SV. Immunoassay of antibodies to benz[a]pyren. Exp Oncol 1998; 20: 74–6.

Tang ZM, Ling ZG, Wang CM, et al. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis. PLoS One 2017; 12: 1–21. https://doi.org/10.1371/journal.pone.0182117

Park H, Shiraishi Y, Imoto S, et al. A novel adaptive penalized logistic regression for uncovering biomarker associated with anti-cancer drug sensitivity. IEEE/ACM Trans Comput Biol Bioinform 2017; 14: 771–82. https://doi.org/10.1109/tcbb.2016.2561937

Zhang C, Leng W, Sun C, et al. Urine proteome profiling predicts lung cancer from control cases and other tumors. EBioMedicine 2018; 30: 120–8. https://doi.org/10.1016/j.ebiom.2018.03.009

Downloads

Published

26.05.2023

How to Cite

Studennikov, A., Glushkov, A., & Ustinov, V. (2023). Detection of antibodies against benzo[a]pyrene in blood sera of lung cancer patients by ELISA using human recombinant idiotypic and anti-idiotypic antibodies. Experimental Oncology, 43(4), 322–327. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17126

Issue

Vol. 43 No. 4 (2021): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.